CoChat

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis

Open access

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/or DLco <35%) and less advanced (percent predicted FVC ≥50% and DLco ≥35%).Overall, 596 patients with baseline FVC and/or DLco values available were included in the analyses; 187 patients had more advanced disease, and 409 patients had less advanced disease. Mean percent predicted FVC declined throughout 180 weeks of treatment in both more and less advanced disease subgroups. Both subgroups exhibited a similar pattern of adverse events; however, adverse events related to IPF progression were experienced by a higher proportion of patients with more advanced versus less advanced disease. Discontinuation rates due to any reason, adverse events related to IPF progression, or deaths were each higher in the more advanced versus the less advanced disease subgroup.These analyses found that longer-term pirfenidone treatment resulted in a similar rate of lung function decline and safety profile in patients with more advanced versus less advanced IPF, and the data suggest that pirfenidone is efficacious, well tolerated, and a feasible treatment option in patients with more advanced IPF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-019-1021-2

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mean percent predicted FVC over time by IPF severity at baseline in RECAP. *Patients with missing percent predicted FVC and DLco values were excluded. FVC Forced vital capacity, DLco Carbon monoxide diffusing capacity, IPF Idiopathic pulmonary fibrosis, SD Standard deviation
Fig. 1 Mean percent predicted FVC over time by IPF severity at baseline in RECAP. *Patients with missing percent predicted FVC and DLco values were excluded. FVC Forced vital capacity, DLco Carbon monoxide diffusing capacity, IPF Idiopathic pulmonary fibrosis, SD Standard deviationCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 48

Metadata

Authors
Costabel, U., Albera, C., Glassberg, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K.-U., & Noble, P. W.
Affiliations
  • Ruhrlandklinik (DE)
  • University of Turin (IT)
  • University of Miami Health System (US)
  • Vanderbilt University Medical Center (US)
  • Universitair Ziekenhuis Leuven (BE)
  • F. Hoffmann-La Roche AG (CH)
  • Cedars-Sinai Medical Center (US)
Corresponding author
Costabel, Ulrich
Venue
Respiratory Research
Published
2019-03-12
Volume
20
Issue
1
Pages
55-55
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W2939662940
Cited by
43
References
9
Citations by year
2025: 2 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 10 · 2020: 16 · 2019: 3
FWCI
5.88
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Respiratory Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
F. Hoffmann-La Roche, Ltd. (.)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
pirfenidone, idiopathic pulmonary fibrosis, advanced disease, lung function decline, forced vital capacity, diffusing capacity for carbon monoxide, disease progression, adverse events, treatment discontinuation, post hoc analysis
MeSH terms
Aged, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Male, Middle Aged, Pyridones, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-019-1021-2
The paper
Costabel, U., Albera, C., Glassberg, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K.-U., & Noble, P. W. (2019). Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-019-1021-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.